The National Cancer Institute's Clinical Proteomic Technologies for Cancer Initiative this week issued a request for targets for monoclonal antibody production and characterization as part of its Antibody Characterization Program.
The organization will accept submissions through July 9 and will review them "based on their justification and contribution to existing NCI-funded projects," the request said. It added that "priority will be given to projects applying the antibodies to proteomics research."
The Antibody Characterization Program generates monoclonal antibodies to proteins associated with human cancer for use in the CPTC initiative. Three antibodies are generated for each protein target and characterized using assays including isotype, SDS-PAGE, Western blot, ELISA, immunohistochemistry, immuno mass spectroscopy, and surface plasmon resonance.
Antibodies and hybridoma cells are made available to researchers through the Developmental Studies Hybridoma Bank at the University of Iowa and other third-party resources.
Successful applicants will be notified on or before Aug. 30. All materials – i.e. proteins or peptides – to be used for antibody development must be ready and available at the time of the request submission.